Viridian Therapeutics Inc
VRDN31.880USD
-0.400-1.24%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.62BMarket Cap
LossP/E TTM
More Details of Viridian Therapeutics Inc Company
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian Therapeutics Inc Info
Ticker SymbolVRDN
Company nameViridian Therapeutics Inc
IPO dateJun 18, 2014
CEOMahoney (Stephen)
Number of employees143
Security typeOrdinary Share
Fiscal year-endJun 18
Address221 Crescent Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone16172724600
Websitehttps://www.viridiantherapeutics.com/
Ticker SymbolVRDN
IPO dateJun 18, 2014
CEOMahoney (Stephen)
Company Executives of Viridian Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Arlene M. Morris
Ms. Arlene M. Morris
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen (Steve) Mahoney
Mr. Stephen (Steve) Mahoney
President, Chief Executive Officer, Director (Principal Executive Officer)
President, Chief Executive Officer, Director (Principal Executive Officer)
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas W. Beetham
Mr. Thomas W. Beetham
Chief Operating Officer
Chief Operating Officer
7.00K
+40.00%
Mr. Seth Harmon
Mr. Seth Harmon
Chief Financial Officer
Chief Financial Officer
2.61K
+161.40%
Ms. Jennifer Tousignant
Ms. Jennifer Tousignant
Chief Legal Officer
Chief Legal Officer
1.54K
--
Ms. Jennifer K. Moses
Ms. Jennifer K. Moses
Independent Director
Independent Director
--
--
Mr. Jeff Ajer
Mr. Jeff Ajer
Independent Director
Independent Director
--
--
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
75.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.42%
Deep Track Capital LP
5.64%
BlackRock Institutional Trust Company, N.A.
4.95%
Kynam Capital Management LP
4.64%
The Vanguard Group, Inc.
4.52%
Other
68.83%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.42%
Deep Track Capital LP
5.64%
BlackRock Institutional Trust Company, N.A.
4.95%
Kynam Capital Management LP
4.64%
The Vanguard Group, Inc.
4.52%
Other
68.83%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.70%
Investment Advisor
32.96%
Investment Advisor/Hedge Fund
19.39%
Venture Capital
8.42%
Private Equity
1.53%
Research Firm
1.53%
Pension Fund
0.63%
Bank and Trust
0.38%
Corporation
0.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
368
96.50M
101.72%
-9.82M
2025Q2
368
94.63M
115.87%
-12.44M
2025Q1
387
93.96M
114.21%
-15.28M
2024Q4
381
93.18M
114.36%
-9.55M
2024Q3
354
88.84M
112.43%
+6.26M
2024Q2
331
71.47M
112.09%
-12.60M
2024Q1
329
71.87M
114.62%
-2.66M
2023Q4
309
61.41M
117.06%
+4.73M
2023Q3
286
52.92M
124.61%
-2.63M
2023Q2
276
50.12M
119.65%
-257.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
10.70M
13.11%
+178.22K
+1.69%
Jun 30, 2025
Deep Track Capital LP
5.38M
6.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.77M
5.84%
-329.65K
-6.46%
Jun 30, 2025
Kynam Capital Management LP
4.43M
5.42%
-272.07K
-5.79%
Jun 30, 2025
The Vanguard Group, Inc.
4.49M
5.5%
-54.59K
-1.20%
Jun 30, 2025
Fairmount Funds Management LLC
3.46M
4.24%
+14.10K
+0.41%
Jun 30, 2025
VR Adviser, LLC
3.88M
4.75%
--
--
Jun 30, 2025
Commodore Capital LP
4.88M
5.97%
+575.00K
+13.37%
Jun 30, 2025
Tang Capital Management, LLC
2.84M
3.48%
+50.00K
+1.79%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.74M
3.36%
+646.50K
+30.86%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
3.62%
Virtus LifeSci Biotech Clinical Trials ETF
1.02%
ALPS Medical Breakthroughs ETF
0.82%
State Street SPDR S&P Biotech ETF
0.6%
JPMorgan Healthcare Leaders ETF
0.49%
First Trust Small Cap Growth AlphaDEX Fund
0.43%
iShares Micro-Cap ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.24%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.1%
ProShares Hedge Replication ETF
0.09%
View more
Simplify Propel Opportunities ETF
Proportion3.62%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.02%
ALPS Medical Breakthroughs ETF
Proportion0.82%
State Street SPDR S&P Biotech ETF
Proportion0.6%
JPMorgan Healthcare Leaders ETF
Proportion0.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.43%
iShares Micro-Cap ETF
Proportion0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.24%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.1%
ProShares Hedge Replication ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Date
Type
Ratio
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
Nov 12, 2020
Merger
15→1
FAQs
Who are the top five shareholders of Viridian Therapeutics Inc?
The top five shareholders of Viridian Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 10.70M shares, accounting for 13.11% of the total shares.
Deep Track Capital LP holds 5.38M shares, accounting for 6.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.77M shares, accounting for 5.84% of the total shares.
Kynam Capital Management LP holds 4.43M shares, accounting for 5.42% of the total shares.
The Vanguard Group, Inc. holds 4.49M shares, accounting for 5.50% of the total shares.
Fidelity Management & Research Company LLC holds 10.70M shares, accounting for 13.11% of the total shares.
Deep Track Capital LP holds 5.38M shares, accounting for 6.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.77M shares, accounting for 5.84% of the total shares.
Kynam Capital Management LP holds 4.43M shares, accounting for 5.42% of the total shares.
The Vanguard Group, Inc. holds 4.49M shares, accounting for 5.50% of the total shares.
What are the top three shareholder types of Viridian Therapeutics Inc?
The top three shareholder types of Viridian Therapeutics Inc are:
Fidelity Management & Research Company LLC
Deep Track Capital LP
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
Deep Track Capital LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Viridian Therapeutics Inc (VRDN)?
As of 2025Q3, 368 institutions hold shares of Viridian Therapeutics Inc, with a combined market value of approximately 96.50M, accounting for 101.72% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.15%.
What is the biggest source of revenue for Viridian Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Viridian Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
